Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder.
OBJECTIVE
To assess the impact of comorbid autism spectrum disorders (ASD) on the response to second-generation antipsychotics (SGA) in pediatric bipolar disorder (BPD).


METHODS
Secondary analysis of identically designed 8-week open-label trials of SGA monotherapy (risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole) in youth with BPD.


RESULTS
Of the 151 BPD subjects 15% (n= 23) met criteria for comorbid ASD. There were no differences in the rate of antimanic response (YMRS change ≥30% or CGI-Improvement ≤2: 65% vs. 69%; P= 0.7) in the presence of comorbid ASD.


CONCLUSIONS
No difference observed in the rate of antimanic response or tolerability to SGA monotherapy in the presence of ASD comorbidity.
Pediatric Psychopharmacology Research Department, Massachusetts General Hospital, USA. Joshi.Gagan@mgh.harvard.edu
Gagan
G
Joshi
Joseph
J
Biederman
Janet
J
Wozniak
Robert
R
Doyle
Paul
P
Hammerness
Maribel
M
Galdo
Nora
N
Sullivan
Courtney
C
Williams
Kristin
K
Brethel
K Yvonne
KY
Woodworth
Eric
E
Mick
D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation